Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
HMW Verheul, HM Pinedo - Nature Reviews Cancer, 2007 - nature.com
Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with
cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor …
cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor …
[HTML][HTML] Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
KJ Gotink, HMW Verheul - Angiogenesis, 2010 - Springer
Tyrosine kinases are important cellular signaling proteins that have a variety of biological
activities including cell proliferation and migration. Multiple kinases are involved in …
activities including cell proliferation and migration. Multiple kinases are involved in …
Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib
HJ Broxterman, KJ Gotink, HMW Verheul - Drug resistance updates, 2009 - Elsevier
Multiple molecular, cellular, micro-environmental and systemic causes of anticancer drug
resistance have been identified during the last 25 years. At the same time, genome-wide …
resistance have been identified during the last 25 years. At the same time, genome-wide …
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label …
…, DL Van der Peet, HMW Verheul… - The lancet …, 2018 - thelancet.com
Background Both perioperative chemotherapy and postoperative chemoradiotherapy improve
survival in patients with resectable gastric cancer from Europe and North America. To our …
survival in patients with resectable gastric cancer from Europe and North America. To our …
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
…, CJA Punt, JTM Plukker, HMW Verheul… - The lancet …, 2015 - thelancet.com
Background Initial results of the ChemoRadiotherapy for Oesophageal cancer followed by
Surgery Study (CROSS) comparing neoadjuvant chemoradiotherapy plus surgery versus …
Surgery Study (CROSS) comparing neoadjuvant chemoradiotherapy plus surgery versus …
Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial
…, CJA Punt, JTM Plukker, HMW Verheul… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal
cancer followed by surgery study (CROSS) has become a standard of care for patients …
cancer followed by surgery study (CROSS) has become a standard of care for patients …
[HTML][HTML] γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
…, GF de Wit, TW Battaglia, H Gelderblom, HMW Verheul… - Nature, 2023 - nature.com
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance
Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an
important clinical problem, but its underlying mechanisms are largely unknown. We analyzed …
important clinical problem, but its underlying mechanisms are largely unknown. We analyzed …
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α
DZ Qian, SK Kachhap, SJ Collis, HMW Verheul… - Cancer research, 2006 - AACR
Hypoxia-inducible factor 1α (HIF-1α) plays a critical role in transcriptional gene activation
involved in tumor angiogenesis. A novel class of agents, the histone deacetylase (HDAC) …
involved in tumor angiogenesis. A novel class of agents, the histone deacetylase (HDAC) …
[PDF][PDF] Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer
…, J Berkhof, JAE Langius, HMW Verheul - Journal of Clinical …, 2016 - zakboekdietetiek.nl
Purpose Low muscle mass is present in approximately 40% of patients with metastatic
colorectal cancer (mCRC) and may be associated with poor outcome. We studied change in …
colorectal cancer (mCRC) and may be associated with poor outcome. We studied change in …